Payment overview · 2025
General Payments
$870.90
31 reported records · 11 companies
Healthcare provider profile · identity verified
Llewellyn Simon, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LAKE PROVIDENCE, LA · NPI 1063494128
Verified facts
What the public records show
CMS Open Payments records show Llewellyn Simon, M.D. received $870.90 in general payments during 2025 across 31 reported records.
AstraZeneca Pharmaceuticals LP accounted for 33.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Verquvo, Zenpep.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Zenpep by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AIRSUPRA as an associated drug or biological on 165148 records involving 56069 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Airsupra by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 507 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synjardy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 462 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trulicity by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ISENTRESS as an associated drug or biological on 37 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Isentress by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Verquvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $290.29 | 33.3% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $143.11 | 16.4% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $99.40 | 11.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $86.71 | 10.0% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $66.13 | 7.6% | 4 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $62.70 | 7.2% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $45.52 | 5.2% | 3 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $20.14 | 2.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.89 | 2.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.87 | 2.2% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.14 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $825.90 | 30 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $248.07 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $148.37 | 3 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $99.40 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $98.11 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $86.71 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $66.13 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $66.13 | 4 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $62.70 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $45.52 | 3 | 2025 |
Source payment records
|
|||||
| PANCREAZE Normalized: pancreaze |
Drug | VIVUS LLC | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.89 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $18.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 507 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 173 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | AIRSUPRA open payments reported associated product |
CMS Open Payments — General Payments 165148 supporting records · 56069 recipient NPIs · example record 1206131344 |
Airsupra · 2024 Exact normalized brand match · 1 Part D row |
43 | 29 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
507 | 89 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
173 | 38 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
173 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
462 | 63 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | ISENTRESS open payments reported associated product |
CMS Open Payments — General Payments 37 supporting records · 24 recipient NPIs · example record 1238003286 |
Isentress · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
138 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
27 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1206 | 157 |
| Potassium Chloride | Potassium Chloride | 651 | 144 |
| Amlodipine Besylate | Amlodipine Besylate | 567 | 138 |
| Atorvastatin Calcium | Atorvastatin Calcium | 527 | 128 |
| Farxiga | Dapagliflozin Propanediol | 507 | 89 |
| Levothyroxine Sodium | Levothyroxine Sodium | 488 | 78 |
| Mounjaro | Tirzepatide | 462 | 63 |
| Methylprednisolone | Methylprednisolone | 412 | 173 |
| Gabapentin | Gabapentin | 352 | 81 |
| Furosemide | Furosemide | 323 | 81 |
| Losartan Potassium | Losartan Potassium | 320 | 80 |
| Omeprazole | Omeprazole | 311 | 79 |
| Metoprolol Succinate | Metoprolol Succinate | 296 | 70 |
| Xarelto | Rivaroxaban | 286 | 42 |
| Quetiapine Fumarate | Quetiapine Fumarate | 268 | 45 |
| Carvedilol | Carvedilol | 267 | 56 |
| Hydralazine Hcl | Hydralazine Hcl | 265 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 241 | 51 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 220 | 131 |
| Famotidine | Famotidine | 210 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 202 | 60 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 198 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 180 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 179 | 46 |
| Donepezil Hcl | Donepezil Hcl | 173 | 35 |
| Jardiance | Empagliflozin | 173 | 38 |
| Fluconazole | Fluconazole | 157 | 67 |
| Allopurinol | Allopurinol | 153 | 42 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 153 | 28 |
| Clindamycin Hcl | Clindamycin Hcl | 141 | 87 |
| Prednisone | Prednisone | 140 | 77 |
| Eliquis | Apixaban | 138 | 16 |
| Lisinopril | Lisinopril | 135 | 35 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 129 | 54 |
| Azithromycin | Azithromycin | 127 | 86 |
| Fluticasone Propionate | Fluticasone Propionate | 127 | 63 |
| Nifedipine Er | Nifedipine | 125 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 124 | 26 |
| Azelastine Hcl | Azelastine Hcl | 120 | 56 |
| Nebivolol Hcl | Nebivolol Hcl | 118 | 24 |
| Levofloxacin | Levofloxacin | 110 | 86 |
| Mupirocin | Mupirocin | 108 | 54 |
| Trazodone Hcl | Trazodone Hcl | 105 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 104 | 28 |
| Clonidine Hcl | Clonidine Hcl | 102 | 16 |
| Sertraline Hcl | Sertraline Hcl | 102 | 28 |
| Temazepam | Temazepam | 101 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 100 | 28 |
| Tramadol Hcl | Tramadol Hcl | 95 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 94 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 93 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 91 | 24 |
| Memantine Hcl | Memantine Hcl | 90 | 22 |
| Glimepiride | Glimepiride | 89 | 23 |
| Spironolactone | Spironolactone | 81 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 80 | 17 |
| Clonazepam | Clonazepam | 79 | 19 |
| Finasteride | Finasteride | 79 | 18 |
| Divalproex Sodium | Divalproex Sodium | 77 | 13 |
| Valacyclovir | Valacyclovir Hcl | 77 | 37 |
| Bupropion Xl | Bupropion Hcl | 76 | 17 |
| Dapagliflozin | Dapagliflozin Propanediol | 75 | 36 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 75 | 44 |
| Januvia | Sitagliptin Phosphate | 72 | suppressed |
| Trulance | Plecanatide | 71 | 20 |
| Nystatin | Nystatin | 70 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 24 |
| Linzess | Linaclotide | 68 | 18 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 66 | 23 |
| Levetiracetam | Levetiracetam | 66 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 65 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 62 | 41 |
| Ezetimibe | Ezetimibe | 61 | 18 |
| Tradjenta | Linagliptin | 60 | suppressed |
| Colchicine | Colchicine | 58 | 22 |
| Lansoprazole | Lansoprazole | 58 | 15 |
| Dexlansoprazole Dr | Dexlansoprazole | 55 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 54 | 14 |
| Entresto | Sacubitril/Valsartan | 54 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 54 | 13 |
| Cefuroxime | Cefuroxime Axetil | 52 | 42 |
| Mirtazapine | Mirtazapine | 52 | 27 |
| Alendronate Sodium | Alendronate Sodium | 51 | 14 |
| Pregabalin | Pregabalin | 48 | suppressed |
| Meloxicam | Meloxicam | 47 | 21 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 46 | 27 |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 46 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 46 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 45 | 32 |
| Trulicity | Dulaglutide | 45 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 45 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 44 | 12 |
| Metformin Hcl | Metformin Hcl | 44 | 14 |
| Airsupra | Albuterol Sulfate/Budesonide | 43 | 29 |
| Enulose | Lactulose | 43 | 14 |
| Olanzapine | Olanzapine | 42 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 42 | 23 |
| Amiodarone Hcl | Amiodarone Hcl | 41 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 39 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | suppressed |
| Dutasteride | Dutasteride | 38 | suppressed |
| Aripiprazole | Aripiprazole | 37 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 36 | suppressed |
| Sucralfate | Sucralfate | 36 | 25 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 35 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 33 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 32 | 12 |
| Montelukast Sodium | Montelukast Sodium | 32 | suppressed |
| Simvastatin | Simvastatin | 32 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | 11 |
| Nitroglycerin | Nitroglycerin | 31 | 13 |
| Methimazole | Methimazole | 30 | suppressed |
| Ozempic | Semaglutide | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | 11 |
| Methocarbamol | Methocarbamol | 28 | 14 |
| Methotrexate | Methotrexate Sodium | 28 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 28 | suppressed |
| Repatha Sureclick | Evolocumab | 28 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 27 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 26 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 26 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Risperidone | Risperidone | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 23 | 21 |
| Alprazolam | Alprazolam | 22 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Novolog | Insulin Aspart | 22 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 20 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 21 | 15 |
| Phenobarbital | Phenobarbital | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | 12 |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 20 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 20 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 20 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 20 | 16 |
| Ondansetron Odt | Ondansetron | 20 | 13 |
| Rivastigmine | Rivastigmine Tartrate | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Constulose | Lactulose | 19 | suppressed |
| Creon | Lipase/Protease/Amylase | 19 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Lubiprostone | Lubiprostone | 19 | suppressed |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 18 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 18 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 18 | suppressed |
| Verquvo | Vericiguat | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Roflumilast | Roflumilast | 17 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 16 | 16 |
| Methylprednisolone Acetate | Methylprednisolone Acetate | 16 | suppressed |
| Novolin R | Insulin Regular, Human | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | 14 |
| Humalog | Insulin Lispro | 15 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 15 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 14 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 13 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 14 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 14 | suppressed |
| Xifaxan | Rifaximin | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Humulin R | Insulin Regular, Human | 13 | 11 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Minoxidil | Minoxidil | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Advocate Pen Needles | Pen Needle, Diabetic | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Cefaclor | Cefaclor | 11 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Dexilant | Dexlansoprazole | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 11 | suppressed |
| Isentress | Raltegravir Potassium | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $870.90 · 31 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, BREZTRI, COMIRNATY, FARXIGA, IBSRELA, INSPIRE, JARDIANCE, OTEZLA, PANCREAZE, PREVNAR 20, REPATHA, VERQUVO, Veozah, ZENPEP, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Aimmune Therapeutics, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error